Brii Biosciences Limited

US
BRIBF
Promotion
Rentabilité pendant six mois: +93.16%
Rendement des dividendes: 0%

0.26 $

0 $ 0%
0.1255 $
0.3042 $

Min./max. pendant un an

Calendrier de promotion Brii Biosciences Limited

Les principaux paramètres

Devise
usd
Industrie
Biotechnology
La monnaie du rapport
cny
Secteur
Health Care
Site web

Grade

Sous-estimation
Nom Signification Grade
P/S 0 0
P/BV 0.2571 10
P/E 0 0
Efficacité
Nom Signification Grade
ROA -17.21 0
ROE -17.6 0
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement des dividendes 0 0
DSI 0 0
La croissance moyenne des dividendes 0 0
Devoir
Nom Signification Grade
Debt/EBITDA 0 10
Debt/Ratio 0.0104 10
Debt/Equity 0.0386 10
Pouls de croissance
Nom Signification Grade
Revenus, milliards, % -78.73 0
Ebitda, % -67.51 0
EPS, % -93.76 0

Prix

Prix Min. Max. Changement Changements dans l'industrie Changements dans l'index
Hier 0.26 $ 0 $ 0 $ 0 % 0 % 0 %
Semaine 0.26 $ 0 $ 0 $ 0 % 0 % 0 %
Mois 0.26 $ 0 $ 0 $ 0 % 0 % 0 %
3 mois 0.3042 $ 0.26 $ 0.26 $ -14.53 % 0 % 0 %
Six mois 0.1346 $ 0.1346 $ 0.3042 $ +93.16 % 0 % 0 %
Année 0.1255 $ 0.1255 $ 0.3042 $ +107.17 % 0 % 0 %
3 ans 1.25 $ 0.0028 $ 1.25 $ -79.2 % 0 % 0 %
5 ans 0.0028 $ 0.0028 $ 2.75 $ +9 285.71 % 0 % 0 %
10 ans 0.0028 $ 0.0028 $ 2.75 $ +9 285.71 % 0 % 0 %
Année à ce jour 0.1255 $ 0.1255 $ 0.3042 $ +107.17 % 0 % 0 %

La gestion de l'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Dr. Zhi Hong Ph.D. Co-founder, Executive Chairman of the Board & CEO 1964 (61 année)
Dr. Ankang Li C.F.A., J.D., Ph.D. Chief Financial & Strategy Officer, Company Secretary and Executive Director 1979 (46 années)
Dr. Eleanor de Groot Ph.D. Chief Technology Officer 1969 (56 années)
Dr. Brian Alvin Johns Ph.D. Chief Scientific Officer
Sarah Qiu Associate Director of Investor Relations
Ms. Karen Del Barrio Neuendorff Chief People Officer & Head of Human Resources 1976 (49 années)
Mr. Coy Stout Head of Patient Advocacy 1972 (53 années)
Dr. Lianhong Xu Ph.D. Head of Discovery 1967 (58 années)
Dr. Qing Zhu Ph.D. Head of China Research & Development 1968 (57 années)
Dr. David Margolis M.D., M.P.H. Chief Medical Officer 1975 (50 années)

Informations sur l'entreprise

Adresse: China, Beijing, Building 7 International Science Park - Ouvert sur google cards, Cartes yandex ouvertes
Site web: https://www.briibio.com

À propos de l'entreprise Brii Biosciences Limited

Brii Biosciences Limited engages in the research and development of therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, BRII-835, and BRII-877, which are in Phase 2 the development of a functional cure for HBV for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 2; and BRII-732 that is in Phase 1 clinical trial and BRII-753, which is in preclinical stage for the treatment of HIV. It develops BRII-296 for the treatment of PPD/MDD, anxiety, and other depressive disorders; BRII-297 for treatment of various depressive disorders; BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for oral treatment for patients with chronic NTM lung disease. Brii Biosciences Limited was incorporated in 2017 and is headquartered in Beijing, China.